Parkinson’s Disease

What goes wrong in Parkinson's

Parkinson's disease destroys a small population of neurons in the brain that produce the neurotransmitter dopamine. Their loss disrupts the brain's control of movement — which is why the most familiar symptoms are tremor, stiffness, and slowed motion.

The molecular driver is misfolded α-synuclein, a protein normally present at synapses throughout the brain. In Parkinson's, copies of α-synuclein clump into dense fibrillar aggregates called Lewy bodies inside neurons. The cells most affected sit in the substantia nigra — the same dopamine-producing population whose loss causes the movement symptoms.

Like Alzheimer's and Huntington's, Parkinson's is fundamentally a protein-misfolding disease. Unlike Huntington's, no single mutation accounts for most cases — most Parkinson's is sporadic, and the pathway from healthy α-synuclein to toxic aggregates is still being worked out.

What Folding@home is doing

Folding@home's main protein-misfolding work to date has been on Alzheimer's, Huntington's, and viral targets like COVID. Parkinson's has remained a smaller, pilot-stage effort — driven by where collaborator labs and funding aligned, not by the underlying science.

The science argues for more. α-synuclein aggregation is exactly the kind of slow, stochastic process Folding@home was built to simulate — too fast for experiments to catch the dangerous intermediates, too slow for any single computer to follow. Expanded work on α-synuclein depends on continued donor compute and on the kind of lab partnerships that have driven the project's progress on Alzheimer's and Huntington's.

Every CPU and GPU joining grows the capacity that lets new disease projects start.